



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **YAMADA, Yoshiji, et al.**

Group Art Unit: **3762**

Serial No.: **10/517,605**

Examiner: **Not Yet Assigned**

Filed: **December 21, 2004**

**P.T.O. Confirmation No.: 1240**

For: **METHOD OF DIAGNOSING RISK OF MYOCARDIAL INFARCTION**

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

February 22, 2006

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. In compliance with applicants duty of disclosure under 37 C.F.R. 1.56, enclosed herewith is a copy of the Supplementary European Search Report along with copies of the references cited therein. The Supplementary European Search Report was cited during the prosecution of the corresponding European patent application No. 03712817.0 (PCT/JP0303477).

The undersigned hereby certifies

**XX** that each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR § 1.56(c) more than thirty days prior to the filing of this statement.

No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the issuance of a first official action on the merits or expiration of the three month period following the filing date or the entry of the national stage of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.

In the event that any fees are due in connection with this paper, please charge our Deposit Account No. 01-2340.

Respectfully submitted,

ARMSTRONG, KRATZ, QUINTOS,  
HANSON & BROOKS, LLP

  
Daniel A. Geselowitz, Ph.D.

Agent for Applicants

Reg. No. 42,573

DAG/rk

Atty. Docket No. **040677**

Suite 1000

1725 K Street, N.W.

Washington, D.C. 20006


(202) 659-2930



**23850**

PATENT TRADEMARK OFFICE

Enclosures: PTO-1449; Supplementary European Search Report; References (13)



<b>INFORMATION DISCLOSURE CITATION PTO-1449</b>	Patent No. <b>040677</b>	Serial No. <b>10/517,605</b>
	Applicant(s): <b>YAMADA, Yoshiji, et al.</b>	
	Filing Date: <b>December 21, 2004</b>	Group Art Unit: <b>3762</b>

### U.S. PATENT DOCUMENTS

Examiner Initial	Document No.	Name	Date	Class	Subclass	Filing Date (If appropriate)
_____	AA	2005-0089914	Yamasaki			04/28/2005
_____	AB					

### FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Translation (Yes or No)
_____	AC 01/79234	10/25/2001	PCT	
_____	AD 91/13075	09/05/1991	PCT	Abstract only.
_____	AE 01/18250	03/15/2001	PCT	
_____	AF 03/087360	10/23/2003	PCT	Abstract only.
_____	AG			

### OTHER DOCUMENTS

_____	AH	PASTINEN, T., et al. "Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population;" <i>Human Molecular Genetics</i> ; Vol. 7, No. 9; pp.1453-1462 (1998).		
_____	AI	LI, A., et al. "Relationship of the C242T <i>p22phox</i> Gene Polymorphism to Angiographic Coronary Artery Disease and Endothelial Function;" <i>American Journal of Medical Genetics</i> ; Vol. 86, pp.57-61 (1999).		
_____	AJ	RAURAMAA, R., et al. "Stromelysin-1 and Interleukin-6 Gene Promoter Polymorphisms Are Determinants of Asymptomatic Carotid Artery Atherosclerosis;" <i>Arterioscler Thromb Vasc Biol.</i> ; Vol. 20; pp.2657-2662 (2000).		
_____	AK	HUMPHRIES, S., et al. "The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study;" <i>Atherosclerosis</i> ; Vol. 139, pp.49-56 (1998).		
<table border="1"><tr><td>Examiner</td><td>Date Considered</td></tr></table>			Examiner	Date Considered
Examiner	Date Considered			



<b>INFORMATION DISCLOSURE CITATION PTO-1449</b>	Atty. Docket No. <b>040677</b>	Serial No. <b>10/517,605</b>
	Applicant(s): <b>YAMADA, Yoshiji, et al.</b>	
	Filing Date: <b>December 21, 2004</b>	Group Art Unit: <b>3762</b>

### U.S. PATENT DOCUMENTS

Examiner Initial	Document No.	Name	Date	Class	Subclass	Filing Date (If appropriate)
_____	BA					
_____	BB					

### FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Translation (Yes or No)
_____	BC		
_____	BD		

### OTHER DOCUMENTS

_____	BE	YE, S., et al. "Progression of Coronary Atherosclerosis Is Associated with a Common Generic Variant of the Human Stromelysin-1 Promoter Which Results in Reduced Gene Expression;" <i>The Journal of Biological Chemistry</i> ; Vol. 271, No. 22. pp.13055-13060 (1996).		
_____	BF	BOEKHOLDT, S., et al. "Genetic Variation in Coagulation and Fibrinolytic Proteins and Their Relation With Acute Myocardial Infarction;" <i>Circulation</i> ; Vol. 104, pp.3063-3068 (2001).		
_____	BG	YAMADA, Y., et al. "PREDICTION OF THE RISK OF MYOCARDIAL INFARCTION FROM POLYMORPHISMS IN CANDIDATE GENES;" <i>The New England Journal of Medicine</i> ; Vol.347, No. 24, pp. 1916-1923 (2002).		
_____	BH	GRUTTERS, J., et al. "Increased Frequency of the Uncommon Tumor Necrosis Factor-857T allele in British and Dutch Patients with Sarcoidosis;" <i>AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE</i> ; Vol. 165, pp.1119-1124 (2002).		
<table border="1"> <tr> <td>Examiner</td> <td>Date Considered</td> </tr> </table>			Examiner	Date Considered
Examiner	Date Considered			